Porto

• This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-504869-23-00 11 2023-05-31 Dermatitis atopic
• Bioequivalence of Eltrombopag 75 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions. Ended
  2022-502702-32-00 2 2023-05-30 Aplastic anemia
• Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy Subjects Ended
  2022-501327-25-00 2 2023-05-13 Advanced or recurrent endometrial carcinoma in adults who have disease
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ended
  2023-508735-31-00 5 2023-05-05 Pulmonary Arterial Hypertension (PAH)
• Bioequivalence of Testosterone Transdermal Gel in Healthy Female Subjects Ended
  2022-501514-56-00 2 2023-05-02 Male hypogonadism
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended
  2022-501540-15-00 5 2023-04-25 Atopic Dermatitis
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• A Randomized, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Relative Bioavailability of LY03010 versus Xeplion® after Intram … Ended
  2022-502179-48-00 2 2023-02-23 Schizophrenia
• STRIDES - A Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia Ended
  2022-501004-10-00 10 2023-01-30 Spinocerebellar Ataxia type-3 (SCA3)
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• Bioequivalence of Oxazepam 50 mg Orodispersible Tablets Versus Seresta® 50 mg Tablets in Healthy Subjects. Ended
  2022-501135-16-00 2 2022-12-26 No medical condition is being investigated. This is a comparative bioa
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytis … Ended
  2022-500921-34-00 3 2022-12-13 Nicotine addiction
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• VItamin C in Thermal injuRY: The VICToRY Trial A phase III multi-center randomized trial Ended
  2023-504772-21-00 4 2022-11-22 Severely burned patients
• A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with Hereditary Angioedema. Ended
  2023-505904-41-00 5 2022-11-17 Hereditary Angioedema Type I or II
• A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment … Ended
  2022-500774-34-00 3 2022-11-08 Urticaria
• A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment co … Ended
  2022-500775-31-00 3 2022-11-08 Allergic rhinitis
• VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended
  2022-500079-30-00 5 2022-11-03 IgA Nephropathy
• Bioequivalence of Oxazepam 10 mg Orodispersible Tablets Versus Seresta® 10 mg Tablets in Healthy Subjects Ended
  2022-501134-35-00 2 2022-10-26 No medical condition is being investigated. This is a comparative bioa
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI … Ended
  2023-504270-38-00 4 2022-10-18 In participants with PD-L1–positive and systemic therapy–naive R/M SCC
• A Four Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of Therapeutic and Supratherapeutic Doses of Cytisin … Ended
  2022-500954-40-00 3 2022-10-17 Nicotine addiction
• Comparative Bioavailability of Nilotinib 200 mg Hard Capsules in Healthy Subjects. Ended
  2022-501325-20-00 2 2022-10-06 Primary Philadelphia-chromosome positive leukemia cells from chronic m

Showing 481–504 of 548 trials